Post-thaw viability of cryopreserved hematopoietic progenitor cell grafts: does it matter?

Vrhovac, Radovan and Perić, Zinaida and Jurenec, Silvana and Kardum-Skelin, Ika and Jelić-Puškarić, Biljana and Jakšić, Branimir (2010) Post-thaw viability of cryopreserved hematopoietic progenitor cell grafts: does it matter? Collegium Antropologicum, 34 (1). pp. 163-9. ISSN 0350-6134

Preview

PDF Download (165Kb) | Preview

Croatian abstract

VIJABILNOST PRIPRAVKA KRVOTVORNIH MATIČNIH STANICA NAKON ODMRZAVANJA: IMA LI KLINIČKO ZNAČENJE ILI NE? ----- Vijabilnost pripravka krvotvornih matičnih stanica iz periferne krvi (KMSPK) i njen utjecaj na klinički tijek nakon transplantacije istraživani su kod 81 uzastopne transplantacije (72 autologne i 9 alogeničnih) provedene u bolesnika oboljelih od hematoloških bolesti. Vijabilnost stanica KMSPK odmah nakon sakupljanja bila je 98,6±3,5%, nakon dodatka dimetil sulfoksida 73,3±21,8%, a nakon odmrzavanja 65,2±16,1%. Nije se bitno razlikovala kod bolesnika različitih dijagnoza, dobi, spola, načina na koji su KMSPK mobilizirane, dozi G-CSFa ili broju prikupljenih CD34+ stanica. Pripravci zamrznuti dulje od 60 dana imali su slabiju vijabilnost nakon odmrzavanja u usporedbi s onima koji su bili zamrznuti manje od 60 dana (56,6±15,2% prema 67,6±15,5%, p=0,04). Vijabilnost nakon odmrzavanja nije utjecala na dinamiku hematopoetskog oporavka, no kod bolesnika kojima je vijabilnost pripravka KMSPK bila slabija uočena je sklonost infektivnim komplikacijama. Češće su razvili febrilnu neutropeniju (72,2% prema 50% bolesnika, p=0,05) te su imali više febrilnih dana (2,4±2,6 prema 1,5±2,3, p=0,05) nakon transplantacije. Pokazali smo da transplantacija KMSPK dovodi do hematopoetskog oporavka neovisno o tome koliko je dugo pripravak KMSPK bio zamrznut i neovisno o vijabilnosti stanica nakon odmrzavanja. Time se potvrdila otpornost CD34+ stanica na postupke zamrzavanja i odmrzavanja koji se rutinski provode u svakodnevnoj praksi. Moguće je da koncentracija granulocita u pripravku KMSPK ima utjecaj na razvoj infektivnih komplikacija nakon transplantacije, no taj je fenomen potrebno detaljnije istražiti na većem broju bolesnika.

English abstract

Cell viability in peripheral blood progenitor cell (PBPC) grafts and its influence on the clinical course following transplantation was evaluated in 81 consecutive transplantations (72 autologous, 9 allogeneic) performed in patients with hematological diseases. Viability of cells in PBPC grafts immediately upon collection was 98.6±3.5%, after addition of dimethyl sulfoxide (DMSO) 73.3±21.8%, and post-thaw 65.2±16.1%. It did not differ significantly between patients with different diagnoses, gender, age, type of priming used, dose of G-CSF administered or number of CD34+ cells collected. However, grafts stored for more than 60 days showed lower post-thaw viability compared to the ones thawed in the 60 days following cryopreservation (56.6±15.2% vs. 67.6±15.5%, p=0.04). Post-thaw graft viability did not influence engraftment time, but there was a predisposition towards infectious complications in the post-transplant period in patients receiving grafts with lower percentage of viable cells. They developed febrile neutropenia more often (72.2% vs. 50% of patients, p=0.05) and had more febrile days (2.4±2.6 vs. 1.5±2.3, p=0.05) following transplantation. We have demonstrated that PBPC grafts are capable of long term engraftment regardless of the graft storage time or percentage of viable cells post-thaw, which confirms the robustness of CD34+ cells during the freeze/thaw procedures carried out in daily clinical practice. Granulocyte concentration in PBPC grafts could have an influence on infectious complications following transplantation and needs to be further investigated on a larger number of patients.

Actions (login required)